Edwards Lifesciences' Board Approves New $1 Billion Share Repurchase Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- Key things to know ahead of SK Hynix’s blockbuster US listing
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Edwards Lifesciences (EW) PT Raised to $136 at Jefferies Following Investor Day
December 8, 2017 6:50 AM ESTJefferies raised its price target on Edwards Lifesciences (NYSE: EW) to $136.00 (from $132.00) while maintaining a Buy rating.
Analyst Raj Denhoy highlighted three conclusions from EWs annual investor briefing:
1. With efforts to tap less sick, undiagnosed, and untreated populations along with continued... More
Edwards Lifesciences (EW) PT Raised to $135 at Cowen
December 8, 2017 6:40 AM ESTCowen raised its price target on Edwards Lifesciences (NYSE: EW) to $135.00 (from $130.00) while maintaining a Outperform rating.
Analyst Joshua Jennings said EW's 2018 targets are likely conservative and were well received. Jennings said the update to the WW TAVR franchise leaves room for 2018 upside and... More
